Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109772 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
A Phase 2 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
NCT00109772 is a Phase 2 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 184 participants.
The verdict
NCT00109772, a Phase 2 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.
Interventions
- DRUG Placebo
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2005-02 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109772
The ClinicalTrials.gov registry entry for NCT00109772 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00109772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109772 about?
NCT00109772 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1". The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Lenalidomide in adult subjects with Complex Regional Pain Syndrome (CRPS) Type 1.
What is the current status of trial NCT00109772?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2005-02. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00109772?
The interventions under investigation include: Placebo (DRUG), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00109772?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.